lesinurad

Generic Name
lesinurad
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C17H14BrN3O2S
CAS Number
878672-00-5
Unique Ingredient Identifier
09ERP08I3W
Background

Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with diuretic-induced hyperuricemi...

Indication

适用与一种黄嘌呤氧化酶抑制剂（别嘌醇、苯溴马隆、非布司他等）联用为与痛风关联高尿酸血症的治疗。一般不单药使用。

Associated Conditions
Hyperuricemia
Associated Therapies
-
Clinical Trials
Related News

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

First Posted Date
2017-07-24
Last Posted Date
2021-11-04
Lead Sponsor
Ironwood Pharmaceuticals, Inc.
Target Recruit Count
242
Registration Number
NCT03226899
Locations
🇺🇸

Four Rivers Clinical Research, Paducah, Kentucky, United States

🇺🇸

Southern Arizona VA Health Care System, Tucson, Arizona, United States

🇭🇺

Dr Lakatos Ferenc Belgyogyaszati-Kardiologiai Maganrendelo, Békéscsaba, Hungary

and more 113 locations

Lesinurad and Febuxostat Combination Extension Study in Gout

Phase 3
Completed
Conditions
Gout
Interventions
Drug: lesinurad
Drug: febuxostat
First Posted Date
2013-03-11
Last Posted Date
2018-01-30
Lead Sponsor
Ardea Biosciences, Inc.
Target Recruit Count
196
Registration Number
NCT01808144

Lesinurad and Allopurinol Combination Extension Study in Gout

Phase 3
Completed
Conditions
Gout
Interventions
Drug: Lesinurad
First Posted Date
2013-03-11
Last Posted Date
2017-01-24
Lead Sponsor
Ardea Biosciences, Inc.
Target Recruit Count
717
Registration Number
NCT01808131

Single and Multiple Dose Study in Japanese

Phase 1
Completed
Conditions
Gout
Interventions
Drug: Lesinurad
Drug: Placebo
First Posted Date
2012-12-06
Last Posted Date
2013-06-19
Lead Sponsor
Ardea Biosciences, Inc.
Target Recruit Count
40
Registration Number
NCT01744379

Open-Label Lesinurad Monotherapy Extension Study in Gout

Phase 3
Completed
Conditions
Gout
Interventions
Drug: lesinurad
First Posted Date
2012-07-26
Last Posted Date
2016-05-26
Lead Sponsor
Ardea Biosciences, Inc.
Target Recruit Count
143
Registration Number
NCT01650246

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

First Posted Date
2012-01-16
Last Posted Date
2016-05-26
Lead Sponsor
Ardea Biosciences, Inc.
Target Recruit Count
330
Registration Number
NCT01510769

Combining Lesinurad With Allopurinol in Inadequate Responders

Phase 3
Completed
Conditions
Gout
Interventions
Drug: Placebo
Drug: Lesinurad
Drug: Allopurinol
First Posted Date
2012-01-13
Last Posted Date
2016-08-18
Lead Sponsor
Ardea Biosciences, Inc.
Target Recruit Count
607
Registration Number
NCT01510158

Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

Phase 3
Completed
Conditions
Gout
Interventions
Drug: lesinurad
Drug: Placebo
First Posted Date
2012-01-12
Last Posted Date
2016-02-12
Lead Sponsor
Ardea Biosciences, Inc.
Target Recruit Count
214
Registration Number
NCT01508702

Combining Lesinurad With Allopurinol in Inadequate Responders

Phase 3
Completed
Conditions
Gout
Interventions
Drug: Lesinurad
Drug: Placebo
Drug: Allopurinol
First Posted Date
2011-12-16
Last Posted Date
2016-05-26
Lead Sponsor
Ardea Biosciences, Inc.
Target Recruit Count
610
Registration Number
NCT01493531
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy